BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
May 01, 2024 07:00 ET | BioCardia, Inc.
SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
March 13, 2024 07:00 ET | BioCardia, Inc.
BioCardia & StemCardia biotechnology company partnership targets heart failure, the leading cause of death and a condition with limited treatment options